Возраст домена | 8 лет |
Дата окончания | Через 1 год |
ИКС | n/a |
Страниц в Google | 3300 |
Страниц в Яндексе | 3000 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 120193 |
Alexa Country | 25270 |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
Endpoints News – The biopharma world is here
n/a
n/a
UTF-8
85.92 КБ
1 206
8 096 симв.
6 360 симв.
Идет сбор информации... Обновить
Идет сбор информации... Обновить
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
Google Analytics | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 27 Июля 2017 ) | |
Количество ссылок на сайт | 2660 |
Количество доменов, которые ссылаются на сайт | 188 |
Количество найденных анкоров | 190 |
Исходящие (внешние) ссылки домена | 904 |
Количество доменов, на которые ссылается сайт | 203 |
Количество исходящих анкоров | 297 |
Внешние ссылки главной страницы ( 3 ) | |
iubenda.com/privacy-policy/286978 nofollow | Privacy Policy |
twitter.com/endpts nofollow | - |
linkedin.com/company/endpoints nofollow | - |
Внутренние ссылки главной страницы ( 81 ) | |
/ | <img> |
/news/ | All News |
/premium | Premium Stories |
endpts.com/channel/rd/ | R&D |
endpts.com/channel/pharma/ | Pharma |
endpts.com/channel/venture/ | Venture |
endpts.com/channel/people/ | People |
endpts.com/channel/startups/ | Startups |
endpts.com/channel/regulatory/ | Regulatory |
endpts.com/channel/deals/ | Deals |
endpts.com/channel/ipos/ | IPOs |
endpts.com/channel/china/ | China |
endpts.com/channel/cell-gene-tx/ | Cell/Gene Tx |
endpts.com/channel/bioregnum/ | Bioregnum |
endpts.com/channel/peer-review/ | Peer Review |
endpts.com/channel/discovery/ | Discovery |
endpts.com/channel/outsourcing/ | Outsourcing |
endpts.com/channel/ai/ | AI |
endpts.com/channel/special/ | Special |
ukbio19.endpts.com/ | UK Biopharma Summit |
biis19.endpts.com/ | US/China Biopharma Summit #BIIS19 |
careers.endpts.com | Endpoints Careers |
mediakit.endpts.com/webinars | Webinars |
endpts.com/sponsored/ | Sponsored Posts |
endpts.com/channel/biotech-voices/ | Biotech Voices |
mediakit.endpts.com | Advertise |
endpts.com/about-endpoints-news/ | About Us |
endpts.com/subscribe/ | SUBSCRIBE NOW |
endpts.com/fda-asks-why-novartis-took-two-months-to-launch-f... | FDA asks why Novartis took two months to launch formal internal probe, after AveXis flagged data manipulation |
endpts.com/why-would-amgen-want-to-buy-alexion-analysts-call... | Why would Amgen want to buy Alexion? Analysts call hotly rumored takeover unlikely, but seize the moment |
endpts.com/gsks-hal-barron-heralds-their-second-positive-rou... | GSK's Hal Barron heralds their second positive pivotal for crucial anti-BCMA therapy, pointing to a push for quick .... |
endpts.com/prisoner-87850-053-does-not-get-to-add-drug-devel... | Prisoner #87850-053 does not get to add drug developer to his list of credits |
endpts.com/pfizer-astellas-win-priority-review-for-xtandi-sn... | Pfizer, Astellas win priority review for Xtandi sNDA; Hemispherx changes its name |
endpts.com/channel/protocols/ | Protocols |
endpts.com/ignyta-founder-boosts-team-at-his-new-cancer-star... | Ignyta founder boosts team at his new cancer startup; Cytomx CMO hits the exit |
endpts.com/building-on-successful-pd-1-pact-eli-lilly-licens... | Building on successful PD-1 pact, Eli Lilly licenses diabetes drug to Chinese partners at Innovent |
endpts.com/news/ | All News |
endpts.com/sir-andrew-dillon-nices-first-and-only-chief-exec... | Sir Andrew Dillon, NICE's first — and only — chief executive to step down next year |
endpts.com/mhra-to-land-a-new-interim-chief-executive-ahead-... | MHRA to land a new interim chief executive ahead of Brexit |
endpts.com/avexis-scientific-founder-fires-back-at-novartis-... | AveXis scientific founder fires back at Novartis CEO Vas Narasimhan, 'categorically denies any wrongdoing' |
endpts.com/versant-backed-chinook-gets-a-65m-launch-round-fo... | Versant-backed Chinook gets a $65M launch round for its discovery quest in a resurgent kidney field |
endpts.com/finch-grabs-a-53m-round-designed-to-take-their-br... | Finch grabs a $53M round designed to take their ‘breakthrough’ microbiome treatment through a potentially pivotal ... |
endpts.com/johns-hopkins-scientists-raise-137m-megaround-for... | Johns Hopkins scientists raise $137M megaround for a trio of spinouts looking to tackle Alzheimer’s, Parkinson’s ... |
endpts.com/vienna-based-vaccine-developer-themis-signs-pact-... | Vienna-based vaccine developer Themis signs pact with Merck for 'blockbuster indication' |
endpts.com/elanco-to-buy-bayers-animal-health-business-for-7... | Elanco to buy Bayer's animal health business for $7.6B, as dealmaking gathers steam in the sector |
endpts.com/on-the-cusp-of-phi-angelman-focused-biotech-score... | On the cusp of PhI, Angelman-focused biotech scores potential buyout deal from Ultragenyx |
endpts.com/fresh-from-102m-haul-igm-bio-pitches-100m-ipo-as-... | Fresh from $102M haul, IGM Bio pitches $100M IPO as it plots first-in-human trial of new antibodies |
endpts.com/springworks-seeks-115m-to-push-pfizer-drugs-acros... | SpringWorks seeks $115M to push Pfizer drugs across finish line while Satsuma sells migraine play in $86M IPO |
endpts.com/a-budget-biotech-you-likely-never-heard-about-is-... | A budget biotech you likely never heard about is setting a course for Wall Street with some modest ambitions |
endpts.com/premium/ | Premium Stories |
endpts.com/webinar-real-world-endpoints-the-brave-new-world-... | Webinar: Real World Endpoints — the brave new world coming in building franchise therapies |
endpts.com/bayers-240m-upfront-for-bluerock-acquisition-puts... | Bayer’s $240M upfront for BlueRock acquisition puts them in the high rollers club for preclinical biotech buyouts |
endpts.com/novartis-18-5b-in-ma-under-vas-narasimhan-says-a-... | Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy |
endpts.com/what-makes-hal-barron-tick-look-at-the-people-hes... | What makes Hal Barron tick? Look at the people he’s teaming up with at GSK |
endpts.com/dont-miss/ | Don't Miss |
endpts.com/an-emboldened-astrazeneca-splurges-95m-on-a-prior... | UPDATED: An emboldened AstraZeneca splurges $95M on a priority review voucher. Where do they need the FDA to hustle .... |
endpts.com/eight-weeks-between-each-hiv-treatment-gsk-notche... | Eight weeks between each HIV treatment? GSK notches PhIII win as it chases OK for long-acting regimen |
endpts.com/sec-calls-out-little-therapeuticsmd-for-selective... | SEC calls out little TherapeuticsMD for its insider contacts with analysts to boost share price, then halt rout |
endpts.com/pfizer-is-making-a-500m-statement-today-heres-how... | Pfizer is making a $500M statement today: Here’s how you become a lead player in the booming gene therapy sector |
endpts.com/bains-orly-mishan-joins-pfizers-neuro-spinout-cer... | Bain's Orly Mishan joins Pfizer's neuro spinout Cerevel; Oncolytic virus biotech taps SillaJen exec Helena Chaye as... |
endpts.com/amy-burroughs-to-lead-cleave-therapeutics-cynthia... | Amy Burroughs to lead Cleave Therapeutics; Cynthia Collins clinches Editas CEO job amid historic CRISPR move |
endpts.com/david-apelian-to-steer-tcr-play-at-pitt-spinout-t... | David Apelian to steer TCR play at Pitt spinout; Third Rock scoops Illumina exec as CEO of cancer detection upstart |
endpts.com/peer-review-rubius-recruits-bd-chief-epizyme-hire... | Peer Review: Rubius recruits BD chief; Epizyme hires Novartis vet as CFO |
endpts.com/seer-adds-ex-fda-chief-mark-mcclellan-to-the-boar... | Seer adds ex-FDA chief Mark McClellan to the board; Hercules Capital makes it official for new CEO Scott Bluestein |
endpts.com/astrazenecas-imfinzi-treme-combo-strikes-out-agai... | READ MORE |
endpts.com/amgen-allergan-biosimilar-of-roches-blockbuster-r... | Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study |
endpts.com/mdma-now-in-phase-iii-shows-promise-as-a-ptsd-tre... | MDMA, now in Phase III, shows promise as a PTSD treatment |
endpts.com/clearside-biomedical-predicts-its-uveitis-drug-wi... | Clearside Biomedical predicts its uveitis drug will be rejected, after FDA requests more data |
endpts.com/futility-analysis-augurs-defeat-in-pivotal-trial-... | Futility analysis augurs defeat in pivotal trial testing of NuCana's lead drug in metastatic pancreatic cancer |
endpts.com/fda-decision-on-vertexs-cf-triple-will-come-just-... | FDA decision on Vertex's CF triple will come just ahead of planned CEO shakeup |
endpts.com/one-of-an-mit-spinouts-living-therapeutics-is-kil... | An MIT spinout kills one of its ‘living therapeutics’ after flunking an early-stage study — shares routed |
endpts.com/astrazenecas-diabetes-drug-farxiga-helps-patients... | AstraZeneca's diabetes drug Farxiga helps patients with heart disease and without diabetes in landmark trial |
endpts.com/get-as-much-spravato-as-you-can-trump-orders-va-w... | READ MORE |
endpts.com/nabriva-scores-its-first-antibiotic-approval/ | Novartis spinoff Nabriva finally scores its first antibiotic approval |
endpts.com/im-not-perfect-novartis-chief-vas-narasimhan-almo... | I’m not perfect: Novartis chief Vas Narasimhan almost apologizes in the wake of a new crisis |
endpts.com/celgene-and-the-scientist-who-championed-fedratin... | Celgene and the scientist who championed fedratinib's rise from Sanofi's R&D graveyard win FDA OK |
endpts.com/icer-blasts-fda-ptc-and-sarepta-for-high-prices-o... | ICER blasts FDA, PTC and Sarepta for high prices on DMD drugs Emflaza, Exondys 51 |
endpts.com/the-top-10-franchise-drugs-in-biopharma-history-w... | The top 10 franchise drugs in biopharma history will earn a total of $1.4T (trillion) by 2024 — what does that tell us? |
endpts.com/columbia-scientist-come-ceo-accused-of-improperly... | Scientist-CEO accused of improperly using confidential info from unicorn Alector |
endpts.com/ailing-mallinckrodts-drug-for-rare-life-threateni... | Ailing Mallinckrodt's drug for rare, life-threatening renal condition clears pivotal study |
endpts.com/an-update-on-the-endpoints-business-model-and-how... | Business Model |
Domain Name: ENDPTS.COM
Registry Domain ID: 2010967229_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.google.com
Registrar URL: http://domains.google.com
Updated Date: 2016-09-15T14:26:53Z
Creation Date: 2016-03-10T15:40:58Z
Registry Expiry Date: 2026-03-10T15:40:58Z
Registrar: Google Inc.
Registrar IANA ID: 895
Registrar Abuse Contact Email: registrar-abuse@google.com
Registrar Abuse Contact Phone: +1.8772376466
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS-CLOUD-E1.GOOGLEDOMAINS.COM
Name Server: NS-CLOUD-E2.GOOGLEDOMAINS.COM
Name Server: NS-CLOUD-E3.GOOGLEDOMAINS.COM
Name Server: NS-CLOUD-E4.GOOGLEDOMAINS.COM
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-12-14T01:29:08Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
User-agent: Googlebot-Image
Disallow: /
США - The Dalles - 104.198.110.226
Google Cloud
HTTP/1.1 200 OK
Server: nginx
Date: Sat, 24 Aug 2019 23:03:15 GMT
Content-Type: text/html; charset=UTF-8
Content-Length: 87979
Connection: keep-alive
Keep-Alive: timeout=20
Vary: Accept-Encoding
Vary: Accept-Encoding
Link: ; rel="https://api.w.org/"
WPE-Backend: apache
X-Cacheable: SHORT
Vary: Accept-Encoding,Cookie
Cache-Control: max-age=600, must-revalidate
X-Cache: HIT: 7
X-Pass-Why:
X-Cache-Group: normal
Accept-Ranges: bytes
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"